Dr. Horwitz on the Future of CHOP for T-Cell Lymphoma

Steven M. Horwitz, MD
Published: Saturday, Apr 04, 2015

 
Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the CHOP regiment for t-cell lymphoma.
 
Whether or not CHOP remains a common treatment regiment for t-cell lymphoma depending largely on how combinations that include CHOP do in clinical trials, says Horwitz.
 
If studies including CHOP do not do well, it could eventually be replaced. However it does offer a high response rate and a high cure rate, so it will probably never entirely be abandoned as a treatment option for t-cell lymphoma.
 
Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the CHOP regiment for t-cell lymphoma.
 
Whether or not CHOP remains a common treatment regiment for t-cell lymphoma depending largely on how combinations that include CHOP do in clinical trials, says Horwitz.
 
If studies including CHOP do not do well, it could eventually be replaced. However it does offer a high response rate and a high cure rate, so it will probably never entirely be abandoned as a treatment option for t-cell lymphoma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x